CIK细胞疗法联合TACE治疗原发性肝癌患者临床疗效观察

目的探讨细胞因子诱导的杀伤细胞（CIK）免疫治疗联合肝动脉化疗栓塞（TACE）术治疗原发性肝癌患者的临床疗效。方法选择2012年2月~2014年2月间在本院确诊并行TACE术的67例原发性肝癌患者,按是否联合CIK治疗分为联合治疗组（CIK+TACE）32例和对照组（TACE）35例,比较两组患者外周血T淋巴细胞亚群变化、生活质量（QOL）改善、临床疗效、无进展生存期（PFS）等指标。结果在CIK首次回输后7 d,联合治疗组患者外周血CD3⁺、CD4⁺细胞的比例和CD4⁺/CD8⁺比值分别为（70.32±2.36）%、（32.18±2.27）%和（1.15±0.05）,显著高于CIK细胞治疗前水平[（63.56±2.42）%、（30.34±2.05）%和（0.90±0.05）,P<0.05）];CIK细胞治疗后外周血CD8⁺细胞比例为（29.35±2.95）%,显著低于治疗前水平[（33.28±3.14）%,P<0.05];联合治疗组患者生活质量明显改善,治疗前后Karuafsky评分分别为（74.6.±12.5）和[（83.4±14.7）,P<0.05];联合治疗组部分缓解率为53.1%,与对照组42.9%比,无显著性差异（P>0.05）;联合治疗组中位PFS为16个月,显著高于对照组的9.5个月（P<0.05）;CIK治疗后不良反应轻微,对症处理后均恢复正常。结论CIK细胞免疫疗法联合TACE术较单纯TACE术治疗,可以提高肝癌患者的细胞免疫功能,改善原发性肝癌患者的生存质量,延缓肿瘤进展。     

季德胜蛇药联合TACE治疗中晚期肝癌的临床观察

目的观察季德胜蛇药联合肝动脉化疗栓塞（TACE）治疗中晚期肝癌的疗效。方法中晚期原发性肝癌28例,14例接受季德胜蛇药联合TACE治疗,14例只进行TACE。结果在治疗3月时,联合组肿瘤应答率为78.6%,明显高于对照组的57.1%（P〈0.05）,患者生活质量改善率分别为71.4%和50.0%（P〈0.05）。结论季德胜蛇药联合TACE治疗中晚期肝癌可提高疗效,可改善患者生活质量。     

肝动脉化疗栓塞术联合微波消融治疗原发性大肝癌疗效观察

目的观察肝动脉化疗栓塞术(TACE)联合微波消融治疗原发性大肝癌的疗效。方法将60例大肝癌(肿瘤直径>5 cm)患者按照治疗方法分为观察组28例和对照组32例,观察组采用TACE联合微波消融治疗,对照组仅行TACE。观察两组疗效,ELISA法检测治疗前后血清甲胎蛋白(AFP),记录中位生存时间及6、12、18、24个月累计生存率。结果观察组治疗总有效率为96.4%,对照组为81.3%,两组比较,P<0.05。观察组治疗前后血清AFP水平分别为(399.13±430.214)、(235.31±308.047)U/L,对照组分别为(491.90±439.203)、(609.81±420.135)U/L,两组治疗前与治疗后比较,两组治疗后比较,P均<0.05。观察组中位生存时间为10个月,对照组为7个月。观察组、对照组6个月生存率分别为89%、50%,12个月生存率分别为18%、0,18个月生存率分别为4%、0,24个月生存率分别为0、0,两组6个月、12个月生存率比较,P均<0.05。结论与单行TACE比较,TACE联合微波消融治疗原发性大肝癌疗效较好,且术后患者生存率高。     

冷循环微波消融联合肝动脉灌注化疗栓塞治疗原发性肝癌患者疗效及安全性研究

目的 探讨冷循环微波消融联合肝动脉灌注化疗栓塞（TACE）治疗原发性肝癌患者的疗效和安全性。方法 将72例原发性肝癌患者随机分成观察组和对照组,每组36例。给予观察组冷循环微波消融联合TACE治疗,对照组行单纯TACE治疗,比较总有效率、生存率、血清甲胎蛋白（AFP）变化和不良反应。结果 在治疗后6个月,观察组总有效率（88.9%）显著高于对照组（69.4%,x²=4.12,P=0.04）;观察组2 a生存率（66.7%）显著高于对照组（41.7%,x²=4.5,P=0.03）;观察组血清AFP下降率（83.3%）显著高于对照组（61.1%,P<0.05）;所有患者均未出现严重的不良反应。结论 冷循环微波消融联合TACE治疗原发性肝癌患者安全有效。     

肝动脉栓塞化疗联合肝叶切除术治疗原发性肝癌患者临床疗效观察

目的 观察肝动脉栓塞化疗（TACE）联合肿瘤切除手术治疗原发性肝癌（PLC）患者的临床疗效。方法 2015年10月~2016年10月我院诊治的PLC患者95例,其中47例接受TACE治疗,48例在TACE治疗后1月行手术切除肿瘤治疗,观察并对比两组患者病灶根除和生存率情况。结果 联合组术后病灶清除率、术后1 a生存率、2 a生存率分别为100.0%、83.3%和68.8%,均显著高于TACE组的53.2%、61.7%和46.8%（P<0.05）,术后复发率为16.7%,明显低于对照组的51.1%（P<0.05）;治疗后联合组肝功能指标改善情况显著优于TACE组（P<0.05）;TACE组患者术后出现肺栓塞5例,肿瘤破裂出血2例,肺部感染3例,而联合组出现肺栓塞2例,肝断面胆瘘1例,肿瘤破裂出血1例,肺部感染1例（P<0.05）。结论 在TACE术后再行手术切除肿瘤治疗PLC患者具有一定的临床应用价值。     

CIK细胞输注联合TACE治疗延缓原发性肝癌患者门静脉癌栓的形成

目的 探讨细胞因子诱导的杀伤细胞（CIK）输注联合经动脉插管化疗栓塞术（TACE）治疗原发性肝癌患者延缓门静脉癌栓形成的可能性。方法 选择2010年1月～2014年12月我院收治的原发性肝癌患者44例,22例接受TACE联合CIK细胞输注治疗,另22例只接受TACE治疗。采用Ficoll两步分离法分离外周血单个核细胞,经IFN-γ、抗CD3单克隆抗体和 IL-2诱导,使用流式细胞仪检测细胞CD抗原表达鉴定CIK细胞培养成功,常规行TACE治疗,在TACE治疗半月后输注CIK细胞悬液3次,细胞总数为1.0×109。治疗前后行腹部CT检查,确定门静脉栓子形成情况。结果 治疗后1 m、3 m和6 m,联合组患者门静脉癌栓发生率分别为4.5%、13.6%和27.2%,而TACE组则分别为9.0%、45.5%和63.6%（P<0.05）;在治疗3月时,联合组肿瘤大小为（4.77±1.27）cm,显著低于TACE组[（5.54±1.14）cm,P＜0.05];在治疗3月时,联合组血清甲胎蛋白水平为(83.14±31.91) ng/ml,也显著低于TACE组[(139.24±98.76) ng/ml,P＜0.05];两组肺部、颅脑和骨骼等远处转移发生率无显著性差异（P>0.05）。结论 CIK细胞输注联合TACE可明显减缓原发性肝癌患者门静脉栓子形成的时间,改善肝功能,同时能有效控制肿瘤的生长及扩散。     

经肝动脉化疗栓塞术联合索拉非尼治疗原发性肝癌患者疗效与生存分析

目的 探讨经肝动脉化疗栓塞术（TACE）联合索拉非尼治疗原发性肝癌（PLC）患者的近期疗效和2 a生存情况。方法 2008年1月至2013年12月收治的PLC患者76例,排除远处转移患者。所有患者接受TACE治疗1～3次,44例同时接受索拉非尼治疗。按照2000年世界卫生组织制定的实体瘤治疗疗效评价标准（RECIST）考核疗效,应用Kaplan-Meier 法计算生存率。结果 在完成TACE治疗6月后,在44例接受索拉非尼治疗的患者中,死亡2例,在32例只接受TACE治疗的患者中,死亡3例。在生存的接受联合索拉非尼治疗的42例患者中,完全缓解、部分缓解、疾病稳定和疾病进展率分别为38.1%、50.0%、4.8%和7.1%,而在只接受TACE治疗的29例生存者中,则分别为27.6%、41.4%、13.8%和17.2%,两组差异显著（P<0.05）;联合组1 a和2 a生存率分别为68.2%和43.2%,而只接受TACE治疗组则分别为50.0%和31.3%,两组差异显著（P<0.05）。结论 对于未手术切除的肝癌患者,在进行TACE治疗的同时或以后给予索拉非尼维持治疗可以提高疗效,延长生存期。     

射波刀联合经导管肝动脉化疗栓塞治疗原发性肝癌的疗效及预后分析

目的探讨射波刀联合经导管肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌(直径≥5 cm)的生存率及影响因素。方法研究对象为我院2011年1月—2013年5月收治的110例原发性肝癌患者,55例采用射波刀联合TACE治疗(治疗组),55例单独接受TACE治疗(对照组),均随访至2015年5月1日,比较2组的局部控制率、临床获益率、中位总生存时间(m OS)、中位肿瘤无进展生存时间(m PFS)及术后6、12、18、24个月的生存情况,分析生存率的影响因素。结果在肿瘤病灶局部控制率方面,治疗组为90.91%,显著优于对照组的63.64%(P=0.001)。2组生存曲线差异有统计学意义,术后6、12、18和24个月生存率方面,治疗组分别为96.36%、85.45%、58.18%、38.18%,对照组分别为78.18%、38.18%、30.91%、23.64%。治疗组和对照组的m OS分别为19个月和10个月,m PFS分别为7.0个月和2.5个月。Cox回归模型分析发现,治疗组肿瘤大小和有无腹水是生存率的影响因素。结论对于大肝癌患者,射波刀联合TACE可增加肿瘤局部控制率,有效延缓肿瘤复发,提高生存率,明显优于单纯TACE治疗,可作为直径≥5 cm肝癌治疗选择之一。而肿瘤大小和腹水可能影响既往接受射波刀患者的生存情况。     

经导管肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者临床疗效评价*

目的 评价经导管肝动脉化疗栓塞（TACE）与射频消融（RFA）联合治疗原发性肝癌患者的临床疗效。方法 采用随机数字表法将60例原发性肝癌患者分为联合组30例和TACE组30例,分别给予TACE联合RFA或TACE治疗,对比分析两组患者的近期和远期临床疗效。结果 联合组完全缓解和部分缓解率分别为26.7%和50.0%,显著高于TACE组的6.7%和23.3%,差异均具有统计学意义（P<0.05）;联合组患者生存时间为（2.86±0.48）年,显著长于TACE组的（0.93±0.27） 年,差异具有统计学意义（P<0.05）;联合组患者治疗后1年、2年、3年血清AFP水平分别为（475.4±200.7） μg/L、（416.4±229.0） μg/L、（320.4±243.5） μg/L,显著低于TACE组的（639.1±190.9） μg/L、（623.4±234.6） μg/L、（674.4±300.2） μg/L,差异均具有统计学意义（P<0.05）;联合组患者1 a、2 a、3 a生存率分别为86.7%、66.7%、56.7%,显著高于TACE组的46.7%、26.7%、10.0%,差异均具有统计学意义（P<0.05）。结论 TACE与RFA联合治疗原发性肝癌患者,临床疗效显著。     

抗癌1方治疗原发性肝癌气虚血瘀证11例

目的观察抗癌1方对原发性肝癌气虚血瘀证的治疗效果.方法原发性肝癌气虚血瘀证患者11例，应用抗癌方1（主要由黄芪、莪术等多味中药组成）进行治疗．临床分期均为Ⅲ期．临床分型：弥漫型0例，结节型9例，块状型2例，小癌型8例．AFP阳性7例，肝外转移8例11例患者均为男性，年龄27岁～67岁，平均年龄52．5岁．治疗前病程5mo～8mo，平均病程6mo，患过乙肝者8例，患过甲肝者2例，肝病史不明者1例．1mo为一疗程，一疗程结束后，对患者的临床症状、体征、生存质量、肝功能的改善情况进行比较分析．随访2a，对患者的生存期进行统计分析．结果经抗癌1方治疗1mo后，治愈0例，显效0例，有效9例，无效7例，总有效率为81．8％．生存1a—2a者3例，6mo～1a者4例，2mo～6mo者2例，2mo以下者2例，平均生存期为6．5mo．治疗前患者平均生存质量为32．73±12．72（分）；治疗后其平均生存质量为52．73±19．66（分），差值有非常显著性意义（P＜0．005）．一疗程结束后，肝区疼痛，纳差，乏力，腹壁静脉曲张等症状，体征明显改善（P＜0．005），但肝肿瘤缩小不明显（P＞0．005），治疗后患者肝功能明显改善（P＜0．005）．结论抗癌1方对原发性肝癌有良好的治疗作用．     

肝动脉化疗栓塞联合三维适形放疗治疗原发性肝癌40例

目的:探讨肝细胞性肝癌(HCC)的肝动脉化疗药物栓塞(TACE)联合三维适形放疗(3DCRT)的综合治疗效果.方法:原发性肝癌患者76例,进行前瞻性分组研究,综合治疗组40例行TACE结合3DCRT治疗,对照组36例单纯行TACE治疗.结果:综合治疗组1,2,3年生存率分别为78%,60%,34%;对照组分别为50%,32%,18%(P<0.05).结论:对不能手术切除治疗的原发性肝癌患者,TACE结合3DCRT治疗能明显提高治疗疗效,且无严重毒副作用.     

Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.

BACKGROUND: Transarterial chemoembolization (TACE) is effective for hepatocellular carcinoma (HCC). Considerable amounts of radiocontrast agent are used for TACE and may induce renal dysfunction. METHOD: This study prospectively investigated the incidence and risk factors of acute renal failure (ARF), defined as an increase of serum creatinine level >1.5 mg/dl after TACE. RESULTS: ARF developed in 12 (8.6%) of 140 patients after TACE. Univariate analysis showed that number of treatment sessions (2.3 +/- 1.4 vs 1.3 +/- 1.6, P=0.013), Child-Pugh class B (50% vs 21%, P=0.035) and the occurrence of severe postembolization syndrome (75% vs 30%, P=0.020) were significantly associated with the development of ARF. Multivariate logistic regression analysis disclosed that the proportional increased risk of ARF was 65% for each additional TACE therapy (odds ratio [OR]: 1.65, 95% confidence interval [CI]: 1.13-2.41, P=0.010). Other independent risk factors were Child-Pugh class B (OR: 12.82, 95% CI: 2.44-67.29, P=0.003) and severe postembolization syndrome (OR: 6.64, 95% CI: 1.60-27.49, P=0.009). Four (33%) of the patients with ARF developed irreversible renal function impairment, and diabetes mellitus was the only associated factor (P=0.067) in this group. CONCLUSIONS: ARF after TACE is closely associated with number of treatment sessions, severity of cirrhosis and development of severe postembolization syndrome. Effective preventive measures should be undertaken especially in high-risk patients.     

Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma

BACKGROUND/AIMS: To observe recurrence prevention on hepatocellular carcinoma after hepatectomy by using TACE (transcatheter hepatic arterial chemoembolization) with thymosin alpha1 postoperatively. METHODOLOGY: From January 2000 to December 2002, 57 patients with hepatocellular carcinoma were randomly divided into three groups: Group A (n=18) received hepatectomy plus TACE and thymosin alpha1 postoperatively, group B (n=23) received hepatectomy plus TACE postoperatively and group C (n=16) received hepatectomy only. The recurrent rate, recurrent time and median survival period for the three groups were observed and measured. RESULTS: For group A, B and C, one-year recurrent rates were 83.3%, 87.0% and 87.5% (p=0.926), respectively. The recurrent time were 7.0, 5.0 and 4.0 months (p=0.039), respectively, and the median survival were 10.0, 7.0 and 8.0 months (p=0.002), respectively. CONCLUSIONS: Comprehensive therapy combining TACE plus Talpha1 postoperatively could not decrease the recurrent rate, but it might delay the recurrent time and prolong survival periods for hepatocellular carcinoma patients after hepatectomy.     

Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein

AIM: To evaluate the efficacy of transcatheter arterial chemoembolisation(TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma(HCC) in patients with tumor thrombus extending to the main portal vein.METHODS: From 2009 to 2013, a total of 418 HCC patients with tumor thrombus extending to the main portal vein were enrolled in this study and divided into four groups. These groups underwent different treatments as follows: TACE(n = 307), surgical intervention(n = 54), sorafenib(n = 15) and palliativetreatment(n = 42). Overall survival rates were determined by Kaplan-Meier method, and differences between the groups were identified through log-rank analysis. Cox's proportional hazard model was used to identify the risk factors for survival.RESULTS: The mean survival periods for patients in the TACE, surgical intervention, sorafenib and palliative treatment groups were 10.39, 4.13, 5.54 and 2.82 mo, respectively. For the TACE group, the 3-, 6-, 12-and 24-mo survival rates were 94.1%, 85.9%, 51.5% and 0.0%, respectively. The corresponding rates were 60.3%, 22.2%, 0.0% and 0.0% for the surgical intervention group and 50.9%, 29.5%, 0.0% and 0.0% for the sorafenib group. Evidently, the results in the TACE group were significantly higher than those in the other groups(P 0.0001). Furthermore, no significant difference among survival rates was observed between TACE with/without sorafenib(10.22 mo vs 10.52 mo, P = 0.615). No significant difference in survival rates was also found among the surgical intervention, sorafenib and palliative treatment groups(P 0.05). These values significantly increased after TACE with/without sorafenib compared with other treatments(P 0.05).CONCLUSION: For HCC patients with tumor thrombus extending to the main portal vein, TACE can yield a higher survival rate than surgical intervention or sorafenib treatment.     

Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients.

OBJECTIVE AND DESIGN: Both surgical resection and transcatheter arterial chemoembolization (TACE) are effective treatments for hepatocellular carcinoma (HCC). Few reports have compared the different treatment modalities for resectable HCC based on clinically matched groups. The aim of this study was to compare the survival rate after surgery, TACE or supportive treatment in resectable HCC patients, and also in elderly patients (> or = 70 y/o). METHODS: From 1984 to 1993, 419 consecutive patients with resectable HCC were included in this study. Of these, 311 (74%) underwent resection of tumours and 46 (11%) refused operation, opting instead for TACE. The remaining 62 (15%) who refused both methods of treatment were given supportive care. Univariate and multivariate analyses for prognostic factors and the 5-year survival rate among the groups were studied. RESULTS: Both surgical resection and TACE groups had a better 5-year survival rate than the supportive treatment group (43% and 34% vs. 7%). There was no difference in survival between the surgery and TACE groups. However, the 5-year survival rate was 11% in TACE and 41% in the surgical group when the patients were > or = 70. In multivariate analysis, female sex (P = 0.0466), tumour size < or = 3 cm (P = 0.0001), alpha-fetoprotein (AFP) < 400 U/l (P = 0.0036), single tumour (P = 0.0474), serum creatinine < or = 1.5 mg/dl (P = 0.0006) and alkaline phosphatase (AP) < or = 100 U/l (P = 0.0007) are associated with good prognosis for resectable HCC. CONCLUSION: TACE is an alternative for resectable HCC. Tumour size, tumour number, AFP level, renal function, AP level and female sex are prognostic factors. In elderly people, TACE must be used prudently and has a worse prognosis.     

Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization

AIM: To prospectively evaluate the effi cacy and safety of partial splenic embolization (PSE) combined with transcatheter hepatic arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma (HCC). METHODS: Fifty patients suffering from primary HCC associated with hypersplenism caused by cirrhosis were randomly assigned to 2 groups: group A receiving PSE combined with TACE (n = 26) and group B receiving TACE alone (n = 24). Follow-up examinations included calculation of peripheral blood cells (leukcytes, platelets and red blood cells) and treatment-associated complications. RESULTS: Prior to treatment, there was no signifi cant difference in sex, age, Child-Pugh grade, tumor diameter, mass pathology type and peripheral blood cell counts between the 2 groups. After treatment, leukocyte and platelet counts were significantly higher in group A during the 3-mo follow-up period (P < 0.05), but lower in group B (P < 0.05). Severe complications occurred in 3 patients (11.5%) of group A and in 19 patients (79.2%) of group B (P < 0.05), and there was no significant difference in symptoms of post-embolization syndrome, including abdominal pain, fever, mild nausea and vomiting between the 2 groups (P > 0.05). CONCLUSION: PSE combined with TACE is more effective and safe than TACE alone for patients with HCC associated with hypersplenism caused by cirrhosis.     

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus

AIM:To evaluate the survival benefits of different treatment strategies for hepatocellular carcinoma(HCC)patients with portal vein tumor thrombus(PVTT)and to determine the prognosis factors.METHODS:Between 2007 and 2009,338 HCC patients treated for PVTT were retrospectively studied.The patients were divided into 4 groups that underwent different treatments:the conservative treatment group(n=75),the transarterial chemoembolization(TACE)group(n=86),the hepatic resection group(n=90),and the hepatic resection associated with postoperative TACE group(n=87).Survival rates were determined using the Kaplan-Meier method and differences between the groups were identified through log-rankanalysis.Cox’s proportional hazard model was used to identify the risk factors for survival.RESULTS:The mean survival periods for patients in the conservative treatment,TACE,hepatic resection and hepatic resection associated with postoperative TACE groups were 3.8,7,8.2 and 15.1 mo,respectively.Significant differences were observed in the survival rates.For the surgical resection associated with postoperative TACE group,the survival rates after 1,2 and3 years were 49%,37%and 19%,respectively.These results were significantly higher than those of the other groups(P<0.05).Meanwhile,the 1,2 and 3 year survival rates for the surgical resection group were 28%,20%and 15%,whereas those for the TACE group were17.5%,0%and 0%,respectively.These values significantly increased after hepatic resection compared with those after TACE(P<0.05).CONCLUSION:Surgical resection is the most effective therapeutic strategy for HCC patients with PVTT and results in high hepatic functional reserve.For patients who can tolerate the procedure,postoperative TACE is necessary to prevent recurrence and prolong the survival period.     

Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization

AIM: To evaluate whether cell apoptosis and regeneration were existed in normal liver cells adjacent to carcinoma after transarterial chemoembolization (TACE). METHODS: Fifty rabbits with hepatic carcinoma were divided into 5 groups at random: group A (control group), groups B and C (TACE treatment groups), groups D and E (partial hepatectomy groups). There were 10 rabbits in each group. Rabbits in groups B-E were treated by transarterial chemoembolization (TACE) and partial hepatectomy (PH) respectively. The changes of S-phase cell fraction (SPF), proliferation index (PI) and cell apoptosis in the normal liver tissue were determined with flow cytometry (FCM) after operations on the first and third days. We determined the mitosis index (MI) with histo-pathological method and the apoptosis index (AI) with TUNEL method at the same time. RESULTS: Twenty-four hours after operations, compared with control group, the rabbits in TACE group had much higher index of SPF, PI and MI (MI: t=4.89, P<0.001; SPF:t=5.27, P<0.001; PI: t=4.87, P<0.001). Moreover, the proliferation of liver cells in TACE group was much weaker than that of the cells treated by partial hepatectomy, and the differences were significant (MI: t=7.02, P<0.001; SPF: t=4.06, P<0.001; PI: t=2.70, P<0.05). Seventy-two h after operations, FCM showed a small sub-G1 peak in TACE group and PH group, compared with the control group, but there was no difference between them (t=0.41, P>0.05). TACE showed that AI in the treated rabbits was higher than that in control group (t=3.07, P<0.05), and there were no differences between TACE group and PH group, either (t=0.93, P>0.05). CONCLUSION: Cell apoptosis and regeneration exist in rabbit liver tissues after TACE in some degree, which may be associated with the selective embolization of iodised oil, chemotherapeutic drug and free radical damage.     

扶脾调肝汤联合TACE治疗原发性肝癌疗效及对患者中医证候积分、生化指标和不良反应的影响

目的:研究扶脾调肝汤联合肝动脉插管化疗栓塞(TACE)治疗原发性肝癌(PHC)的疗效及对患者中医证候积分、生化指标和不良反应的影响.方法:选择2017年1月-2020年2月诊治的92例PHC患者,根据非随机临床同期对照研究及患者自愿原则分为TACE组(45例)和联合组(47例),2组患者均给予TACE治疗,联合组于治疗...     

肝动脉化疗栓塞及注射32P-胶体、无水乙醇综合序贯介入治疗原发性肝癌疗效分析

目的 评价肝动脉化疗栓塞及Ｂ超引导下注射＾３２Ｐ－胶体、无水乙醇（ＰＥＩ）综合序贯介入治疗原发性肝癌的临床价值。方法 ５１例中晚期肝癌分为２组,２３例综合序贯应用ＴＡＣＥ＋＾３２Ｐ＋ＰＥＩ治疗,２８例单纯应用ＴＡＱＣＥ治疗。结果 综合序贯组肿瘤缩小率、肿瘤完全坏死率、ＡＦＰ下降率分别为９１．２９％、８０．００％、８７．５％,而单纯ＴＡＣＥ组分别为３９．２７％、３０．４３％、４１．４６％,两组比较有